Understand the source comparison
ARA-290 vs Cerebrolysin: Research Comparison
Mechanism Innate repair receptor (CD131/EPOR) activation → JAK2/STAT3 signaling Exogenous neurotrophic factor mixture (BDNF, NGF, GDNF analogs) → Trk receptor activation ARA-290 activates endogenous pathways; Cerebrolysin supplements factors directly. Choose b
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Mechanism
- Innate repair receptor (CD131/EPOR) activation → JAK2/STAT3 signaling
- Exogenous neurotrophic factor mixture (BDNF, NGF, GDNF analogs) → Trk receptor activation
- ARA-290 activates endogenous pathways; Cerebrolysin supplements factors directly. Choose based on whether you're triggering repair or providing missing components
- Primary Applications
- Small fiber neuropathy, acute TBI, ischemic stroke (preclinical), inflammatory neuropathies
- Alzheimer's disease, vascular dementia, acute ischemic stroke, post-stroke recovery
- ARA-290 suits acute injury models; Cerebrolysin fits chronic neurodegeneration with longer treatment windows
- Clinical Evidence Strength
- Limited. 2 Phase II trials (small fiber neuropathy), strong preclinical neuroprotection data
- Extensive but heterogeneous. 15+ RCTs across stroke, dementia, TBI with variable methodological quality
- Cerebrolysin has volume; ARA-290 has cleaner (but narrower) data. Depends whether breadth or rigor matters more for your research question
- Dosing Range
- 2–8 mg subcutaneous (clinical); 10–100 mcg/kg (preclinical)
- 10–50 mL IV daily (clinical); 2.5–5 mL/kg (preclinical)
- ARA-290 uses receptor saturation dosing; Cerebrolysin uses mass-action dosing. Budget and administration complexity differ dramatically
- Half-Life
- 4–6 hours (rodent), estimated 8–10 hours (human)
- 2–8 hours depending on peptide fraction
- Both require daily or multiple-weekly dosing; neither has extended-release formulations
- Blood-Brain Barrier Penetration
- Minimal in healthy tissue; enhanced penetration at injury sites with compromised BBB
- Partial penetration via receptor-mediated transcytosis; fraction varies by peptide size
- Neither crosses intact BBB efficiently. Both work best when barrier integrity is already compromised by disease or injury
- The bottom line when comparing ARA-290 vs Cerebrolysin: they're not interchangeable. ARA-290's targeted receptor mechanism suits studies where you're activating the body's existing repair machinery. Think acute injuries, inflammatory conditions, or models where you want to measure endogenous pathway activation. Cerebrolysin's neurotrophic cocktail suits studies where you're supplementing what's missing. Chronic neurodegeneration, aging models, or protocols measuring exogenous factor effects on synaptic density or neuronal survival.